Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.


BACKGROUND Anti-tumour necrosis factor (TNF) agents have improved the care of Crohn's disease (CD). After the first anti-TNF discontinuation, it is possible to switch to another anti-TNF. Three anti-TNF agents are available for ulcerative colitis (infliximab, adalimumab and golimumab), but only the first 2 have been approved for CD because golimumab has not… (More)
DOI: 10.1111/apt.14371


3 Figures and Tables